Anzeige
Mehr »
Login
Donnerstag, 05.08.2021 Börsentäglich über 12.000 News von 668 internationalen Medien
Relay Medical im Fokus der Sportwelt! Federer, Nadal & Medvedev...
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 882807 ISIN: US92532F1003 Ticker-Symbol: VX1 
NASDAQ
04.08.21
22:00 Uhr
199,59 Euro
0,00
0,00 %
1-Jahres-Chart
VERTEX PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
VERTEX PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
168,44168,9613:37
168,46168,9813:37

Aktuelle News zur VERTEX PHARMACEUTICALS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiUnderstanding Vertex Pharmaceuticals's Unusual Options Activity17
VERTEX PHARMACEUTICALS Aktie jetzt für 0€ handeln
SaBetter Buy: Vertex vs. CRISPR46
FrVertex (VRTX) Q2 Earnings Beat Estimates, 2021 Guidance Up32
FrCRISPR's Q2 earnings beat thanks to $900M upfront payment from Vertex13
FrVertex Pharmaceuticals Incorporated 2021 Q2 - Results - Earnings Call Presentation11
FrVertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani on Q2 2021 Results - Earnings Call Transcript24
FrVertex Pharmaceuticals Lifts FY21 Revenue Outlook420CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) lifts its full year 2021 revenue outlook. The company now expects revenues of $7.2 billion to $7.4 billion for the full...
► Artikel lesen
29.07.Vertex Pharmaceuticals Inc. Q2 adjusted earnings Beat Estimates232CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) released a profit for second quarter that fell from the same period last year.The company's earnings totaled $67 million...
► Artikel lesen
28.07.Vertex To Initiate Phase 3 Program For Once-Daily Triple Combination Regimen In Cystic Fibrosis275CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) said that it will initiate a phase 3 development program for the new once-daily investigational triple combination of...
► Artikel lesen
28.07.Vertex to initiate Phase 3 program in H2 for new triple combination regimen in cystic fibrosis7
28.07.Vertex Pharmaceuticals Incorporated: Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis245- Phase 2 study met primary endpoint and all secondary endpoints - - Phase 2 data demonstrated that a once-daily triple combination of VX-121/ tezacaftor/VX-561 has potential for enhanced clinical...
► Artikel lesen
26.07.Vertex (VRTX) to Report Q2 Earnings: What's in the Cards?36
22.07.3 Things About Vertex Pharmaceuticals That Smart Investors Know50
20.07.Where Vertex Pharmaceuticals Stands With Analysts38
20.07.Vertex (VRTX) Initiates Phase II Study on Pain Candidate31
10.07.Vertex Pharma: Underestimated64
03.07.What Are the Odds That Vertex Strikes a Big Acquisition Deal?54
01.07.Expert Ratings For Vertex Pharmaceuticals63
01.07.Vertex initiated at Raymond James, Altimmune price target lowered, and more in analyst action109
01.07.Could Vertex Pharmaceuticals Be a Prime Acquisition Target?49
Seite:  Weiter >>
171 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
3,4,37